NYSE$LH

Laboratory Corp Of America Holdings · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Labcorp's Q4 2021 financial performance decreased compared to the previous year due to a decline in COVID-19 testing, while the base business experienced growth.

Labcorp's Q4 2021 revenue was $4.06 billion, a decrease of 9.7% compared to Q4 2020. Diluted EPS was $5.75, down from $9.54 in the same period last year. The company's base business grew by 5.0%, offsetting a decline in COVID-19 testing revenue. Labcorp provided 2022 guidance, including adjusted EPS of $17.25 to $21.25 and free cash flow of $1.7 billion to $1.9 billion.

  • Revenue for Q4 2021 was $4.1 billion, compared to $4.5 billion in the previous year.
  • Diluted EPS for Q4 2021 was $5.75, versus $9.54 last year.
  • Adjusted EPS for Q4 2021 was $6.77, compared to $10.56 last year.
  • Free cash flow for Q4 2021 was $548 million, versus $675 million last year.

Headline financials

Total Revenue

$4.06B

Previous: $4.49B-9.7%
EPS (adj)

$6.77

Previous: $10.56-35.9%
Backlog

$15B

No prior period
Capital Expenditures

$150M

Previous: $99.4M+50.9%
Free Cash Flow

$548M

Previous: $675M-18.9%
Net Income

$553M

Previous: $939M-41.1%
Operating Income

$731M

Previous: $1.29B-43.5%
Gross Profit

$1.38B

Previous: $1.9B-27.8%
Cash & Equivalents

$1.47B

Previous: $1.32B+11.5%
Total Assets

$20.4B

Previous: $20.1B+1.6%
Stock-Based Comp

$42.1M

Previous: $26.8M+57.1%

Revenue & EPS history

LabCorp · Revenue · Quarterly

$4.06B

Q4 2021-9.7%vs Q4 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

LabCorp · $4.08B total across 2 segments · Q4 2021

  • Diagnostics Laboratories
    $2.62B-16.9%
  • Biopharma Laboratory Services
    $1.45B+3.9%

Forward guidance

Labcorp provided full-year 2022 guidance including revenue, adjusted EPS, and free cash flow.

Tailwinds

  • Adjusted EPS of $17.25 to $21.25.
  • Free Cash Flow of $1.7 billion to $1.9 billion.
  • Base Business revenue growth of 7.5% to 10.0%.
  • Total Drug Development revenue growth of 7.0% to 9.5%.
  • Continued Base Business growth in 2022 and beyond.

Headwinds

  • COVID-19 Testing revenue decline of (75.0%) to (60.0%).
  • Total Diagnostics revenue decline of (17.5%) to (11.5%).
  • Impact from foreign currency translation of (0.2%).
  • Impact from foreign currency translation of (0.1%).
  • Impact from foreign currency translation of (0.4%).

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.3%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-0.9%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+9.5%

Q2 2024

Best reaction

-10.4%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.0%+0.0%+1.3%
Q4 2025-2.1%+0.0%-6.6%
Q3 2025-5.7%-7.9%-2.7%
Q2 2025-0.5%+1.2%+2.0%
Q1 2025+4.7%+7.9%+7.5%
Q4 2024-0.9%-1.9%+1.2%
Q3 2024+4.0%+3.7%+9.0%
Q2 2024+9.5%+4.8%+6.7%
Q1 2024-4.6%-3.2%-4.0%
Q4 2023-5.0%-5.5%-8.3%
Q3 2023+0.6%+1.0%+7.6%
Q2 2023-1.9%-2.4%-3.0%
Q1 2023-4.6%-2.5%-8.2%
Q4 2022+3.2%-0.4%-14.1%
Q3 2022-2.5%-3.2%+5.0%
Q2 2022+5.1%+1.2%-8.1%
Q1 2022-5.0%-3.1%+1.9%
Q4 2021-1.9%-6.0%-5.7%
Q3 2021+2.3%+2.0%+3.1%
Q2 2021+4.6%+6.0%+6.1%
Q1 2021+1.2%+4.1%+4.5%
Q4 2020+4.0%+3.1%+4.1%
Q3 2020+1.0%-1.1%-2.7%
Q2 2020-3.3%-4.2%-13.4%
Q1 2020-6.5%-10.4%-0.4%
Q4 2019+4.1%+1.8%-19.5%
Q3 2019-2.0%-2.3%+0.4%
Q2 2019-6.5%-4.2%-6.9%
Q1 2019+3.7%+6.1%+5.1%
Q4 2018+2.5%+3.8%+3.7%
Q3 2018-7.1%-6.2%-4.1%
Q2 2018-5.4%-6.4%-5.3%
Q1 2018+3.9%+2.8%+9.7%
Q4 2017+3.9%+3.0%+5.9%
Q3 2017+1.7%+2.2%+0.2%
Q2 2017+2.0%+1.3%-1.4%
Q1 2017-4.1%-3.1%-1.9%
Q4 2016+2.4%+2.4%+5.4%
Q3 2016-10.4%-9.4%-7.9%
Q2 2016+0.4%+1.2%-1.4%
Q1 2016+4.1%
Q4 2015+2.8%
Q3 2015+7.8%
Q2 2015+3.8%
Q1 2015-2.7%
Q4 2014+4.9%
Q3 2014+3.5%
Q2 2014-0.5%
Q1 2014-0.7%
Q4 2013+1.1%
Q3 2013-3.2%
Q2 2013+0.0%
Q1 2013+0.7%
Q4 2012-1.7%
Q3 2012-4.0%
Q2 2012-9.0%
Q1 2012-3.4%
Q4 2011+2.2%
Q3 2011-6.6%
Q2 2011-0.6%
Q1 2011+1.4%
Q4 2010-0.2%
Q4 2007-0.2%
Q3 2010+1.6%
Q2 2010+0.9%
Q1 2009+1.8%
Q1 2010+1.6%
Q4 2009-0.4%
Q2 2008-1.6%
Q3 2009-1.6%
Q3 2008-1.6%
Q4 2008-1.4%
Q2 2009-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro